Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 62991

1.

Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia.

Bereczki E, Francis PT, Howlett D, Pereira JB, Höglund K, Bogstedt A, Cedazo-Minguez A, Baek JH, Hortobágyi T, Attems J, Ballard C, Aarsland D.

Alzheimers Dement. 2016 May 22. pii: S1552-5260(16)30244-8. doi: 10.1016/j.jalz.2016.04.005. [Epub ahead of print]

PMID:
27224930
2.

Medication Adherence in People With Parkinson Disease.

Shin JY, Habermann B.

J Neurosci Nurs. 2016 May 24. [Epub ahead of print]

PMID:
27224682
3.

Outpatient Titration of Carbidopa/Levodopa Enteral Suspension (Duopa).

Pahwa R, Lyons K.

Int J Neurosci. 2016 May 24:1-16. [Epub ahead of print]

PMID:
27222011
4.

An update on the diagnosis and treatment of Parkinson disease An update on the diagnosis and treatment of Parkinson disease.

Rizek P, Kumar N, Jog MS.

CMAJ. 2016 May 24. pii: cmaj.151179. [Epub ahead of print] Review. No abstract available.

PMID:
27221269
5.

Inflammatory profile in LRRK2-associated prodromal and clinical PD.

Brockmann K, Apel A, Schulte C, Schneiderhan-Marra N, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Gasser T, Schüle B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Marras C, Berg D, Maetzler W.

J Neuroinflammation. 2016 May 24;13(1):122. doi: 10.1186/s12974-016-0588-5.

PMID:
27220776
6.

Striatal Hand Deformity in Parkinson Disease.

Joseph J, Thomas J.

J Clin Rheumatol. 2016 Jun;22(4):219. doi: 10.1097/RHU.0000000000000422. No abstract available.

PMID:
27219313
7.

Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy.

Engeln M, Ansquer S, Dugast E, Bezard E, Belin D, Fernagut PO.

Neuropharmacology. 2016 May 20. pii: S0028-3908(16)30211-8. doi: 10.1016/j.neuropharm.2016.05.013. [Epub ahead of print]

8.

Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents. Non-linear QSAR analyses integrated with pharmacophore modeling.

Khanfar MA, Al-Qtaishat S, Habash M, Taha MO.

Chem Biol Interact. 2016 May 20. pii: S0009-2797(16)30193-4. doi: 10.1016/j.cbi.2016.05.023. [Epub ahead of print]

PMID:
27216633
9.

Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease.

Holtz NA, Tedford SE, Persons AL, Grasso SA, Napier TC.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 May 20. pii: S0278-5846(16)30077-X. doi: 10.1016/j.pnpbp.2016.05.004. [Epub ahead of print]

PMID:
27216282
10.

Advanced therapies in Parkinson's disease: Long-term retrospective study.

Merola A, Espay AJ, Romagnolo A, Bernardini A, Rizzi L, Rosso M, Espay KJ, Zibetti M, Lanotte M, Lopiano L.

Parkinsonism Relat Disord. 2016 May 17. pii: S1353-8020(16)30167-5. doi: 10.1016/j.parkreldis.2016.05.015. [Epub ahead of print]

PMID:
27215392
11.

Parkinsonian Rest Tremor Is Associated With Modulations of Subthalamic High-Frequency Oscillations.

Hirschmann J, Butz M, Hartmann CJ, Hoogenboom N, Özkurt TE, Vesper J, Wojtecki L, Schnitzler A.

Mov Disord. 2016 May 23. doi: 10.1002/mds.26663. [Epub ahead of print]

PMID:
27214766
12.

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.

Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O.

Mov Disord. 2016 May 23. doi: 10.1002/mds.26659. [Epub ahead of print] Review.

PMID:
27214664
13.

Association Between Body Mass Index and Parkinson Disease-Reply.

Wills AM, Boyd J, Pérez A.

JAMA Neurol. 2016 May 23. doi: 10.1001/jamaneurol.2016.1245. [Epub ahead of print] No abstract available.

PMID:
27214659
14.

Tractography-Based Ventral Intermediate Nucleus Targeting: Novel Methodology and Intraoperative Validation.

Sammartino F, Krishna V, Kon Kam King N, Lozano AM, Hodaie M.

Mov Disord. 2016 May 23. doi: 10.1002/mds.26633. [Epub ahead of print]

PMID:
27214406
15.

Association Between Body Mass Index and Parkinson Disease.

Cardoso R, Miranda D, Ferreira JJ.

JAMA Neurol. 2016 May 23. doi: 10.1001/jamaneurol.2016.1242. [Epub ahead of print] No abstract available.

PMID:
27214340
16.

Mavoglurant in Parkinson's Patients With l-Dopa-Induced Dyskinesias: Two Randomized Phase 2 Studies.

Trenkwalder C, Stocchi F, Poewe W, Dronamraju N, Kenney C, Shah A, von Raison F, Graf A.

Mov Disord. 2016 May 23. doi: 10.1002/mds.26585. [Epub ahead of print]

PMID:
27214258
17.

[<sup>123</sup>I]-Ioflupane SPECT in combination with MIBG myocardial scintigraphy in Parkinson's disease: a case series study.

Yamada A, Murakami T, Kang Y, Iikuni Y, Morimatsu A, Shirata A, Ito H, Ugawa Y, Yamane K.

Rinsho Shinkeigaku. 2016 May 21. [Epub ahead of print]

PMID:
27212677
18.

Estrogen modulation of calretinin and BDNF expression in midbrain dopaminergic neurons of ovariectomised mice.

Yii H, Bao X, Tang X, Fan X, Xu H.

J Chem Neuroanat. 2016 May 19. pii: S0891-0618(15)30025-9. doi: 10.1016/j.jchemneu.2016.05.005. [Epub ahead of print]

PMID:
27211874
19.

[Problem solving care models of Parkinson's disease].

Csóka M, Molnár S, Kellős É, Domján G.

Orv Hetil. 2016 May;157(22):855-68. doi: 10.1556/650.2016.30479. Hungarian.

PMID:
27211355
20.

What can trigger the onset of Parkinson's disease - A modeling study based on a compartmental model of α-synuclein transport and aggregation in neurons.

Kuznetsov IA, Kuznetsov AV.

Math Biosci. 2016 May 17. pii: S0025-5564(16)30048-7. doi: 10.1016/j.mbs.2016.05.002. [Epub ahead of print]

PMID:
27211070
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk